Article Details

Asco-GU – Bristol in pole position with Opdivo's adjuvant use

Retrieved on: 2021-02-09 15:44:12

Tags for this article:

Click the tags to see associated articles and topics

Asco-GU – Bristol in pole position with Opdivo's adjuvant use. View article details on hiswai:

Excerpt

A year ago Roche said Tecentriq had failed to extend disease-free survival in this tumour, as tested in Imvigor-010, and though it later presented ...

Article found on: www.evaluate.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up